Related Experiment Video
Updated: Jun 23, 2026
16:19
Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure
Published on: September 13, 2014
Extracorporeal support for patients with hepatic failure
1Royal Free and University College Hospital Medical School, Center for Nephrology, Royal Free Hospital, Pond Street, London, UK. Davenport@rfh.nthames.nhs.uk
Hemodialysis International. International Symposium on Home Hemodialysis
|April 22, 2009
Summary
Extracorporeal liver support systems offer potential therapeutic options for patients with acute liver failure or decompensated cirrhosis. These systems may help patients recover from acute insults, especially those with chronic liver disease and hepatorenal syndrome.
Area of Science:
- Hepatology
- Nephrology
- Critical Care Medicine
Background:
- Acute and chronic liver failure present complex clinical challenges.
- Patients can be categorized into those with ongoing hepatic necrosis and those with chronic decompensation facing acute insults.
- Differentiating these groups is crucial for appropriate management and predicting outcomes.
Purpose of the Study:
- To review the role and evolution of extracorporeal support systems in managing liver failure.
- To explore the potential of these systems for patients with acute liver failure and decompensated cirrhosis.
- To highlight the application of liver support in patients with hepatorenal syndrome.
Main Methods:
- Review of existing literature on extracorporeal liver support.
- Categorization of liver failure patients based on underlying pathology and clinical presentation.
- Discussion of technological advancements in liver support devices.
Main Results:
- Extracorporeal support has evolved from basic dialysis to sophisticated bioartificial devices.
- Liver transplantation remains the primary option for acute liver failure with ongoing necrosis.
- Extracorporeal support and medical therapy may offer recovery for decompensated cirrhosis patients post-insult.
Conclusions:
- Extracorporeal liver support systems represent a developing therapeutic avenue for specific liver failure patient groups.
- Further research is warranted to optimize the use of these systems, particularly in hepatorenal syndrome.
- Tailored management strategies, including extracorporeal support, are essential for improving patient outcomes in liver failure.
Related Concept Videos
01:25Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Hemoperfusion and hemofiltration are critical techniques in medical treatments to eliminate accumulated drugs, metabolites, and electrolytes from the bloodstream. These methods are particularly vital in cases of accidental poisoning and drug overdose.Hemoperfusion involves passing blood through an adsorbent material to remove unwanted substances. The main adsorbents used in hemoperfusion include activated charcoal and Amberlite resins. Activated charcoal can adsorb both polar and nonpolar...
01:26Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...
01:30Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis
Patients with end-stage renal disease (ESRD) or those experiencing drug overdose often require extracorporeal methods to eliminate accumulated drugs and metabolites. Hemoperfusion, hemofiltration, and dialysis are the primary techniques to rapidly remove harmful substances without disrupting the patient's fluid and electrolyte balance. For those with compromised renal function, dosage adjustments of concurrent medications may be necessary during extracorporeal drug removal.Dialysis is a process...
01:21Hepatic Portal System
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is responsible...
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is responsible...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.